Multiply Labs
Robotic automation for biologics manufacturing
CORE INFO
Multiply Labs builds enclosed robotic systems that automate manual steps in biologics production, including handling materials, loading instruments, taking samples, and recording manufacturing data. Pharmaceutical and biotechnology companies buy and operate these systems for cell and gene therapies, antibodies, viral vectors, and mRNA therapies.
- Series B funding of $75 million was announced on October 6, 2026, led by NantWorks and bringing total capital raised to more than $100 million.axios.combizjournals.com
- Business Insider coverage reported that Multiply Labs had deployed a high single-digit number of machines, highlighting the company's early commercial scale and the challenge of turning expensive systems into a repeatable business.cncbnews.com
- AstraZeneca and Legend Biotech are named customers, with collaborations focused on automating cell-therapy manufacturing.bizjournals.combioprocessintl.com
WHY WE WOULD WORK AT MULTIPLY LABS
Expand Patient Access
Help make cell and gene therapies more available by automating the manufacturing bottlenecks that keep advanced treatments expensive and capacity-constrained.
Build Physical AI
Work on a distinctive stack combining collaborative robotic arms, imitation learning, orchestration software, sensors, and electronic batch records for biologics manufacturing.
Shape Biomanufacturing
Develop systems used for cell and gene therapies, antibodies, viral vectors, and mRNA—integrating with real GMP instruments from partners including Thermo Fisher, Cytiva, and GenScript.
Join a Multidisciplinary Team
Collaborate across robotics, mechanical and electrical engineering, software, pharmaceutical science, manufacturing, regulatory, and commercial functions on a team of roughly 70 people.
Scale a Proven Platform
Join during a major growth phase: Multiply Labs has raised $75 million in Series B funding, surpassed $100 million total capital, and deployed a high single-digit number of robotic systems.
Work With Industry Leaders
Build alongside organizations including AstraZeneca, Legend Biotech, Kyverna Therapeutics, Retro Biosciences, Stanford, and Charles River as the platform moves toward commercial-scale deployment.
MARKET AND TRACTION
GROWTH TACTICS
✦ KEY METRICNOTABLE CUSTOMERS
KEY METRICS
✦ KEY METRICCOMPETITIVE ADVANTAGE
MARKET POSITION
PRODUCT AND TECH
Robotic Manufacturing Clusters
Modular, enclosed systems use up to four collaborative robotic arms and 24 instrument modules to automate biologics manufacturing workflows. Pharmaceutical and biotechnology companies can own and operate the clusters in-house.
Biomanufacturing Orchestration
Proprietary software translates manufacturing protocols into coordinated robotic actions, including material handling, instrument loading, sampling, waste management, and parallel process execution.
Closed GMP Automation
Closed, GMP-ready systems automate sterile manufacturing steps for cell and gene therapies, antibodies, viral vectors, and mRNA therapies. The approach reduces manual handoffs and contamination risk while supporting regulated production.
Instrument Integration
Multiply Labs integrates with existing pharmaceutical instruments from manufacturers including Thermo Fisher, Cytiva, GenScript, Fedegari, Akron Bio, and Charles River. This enables automation without replacing validated process equipment.
Process Data Systems
Real-time monitoring records sensor readings, operator and robot interactions, material genealogy, and electronic batch records. The software is designed to integrate with quality systems and support 21 CFR Part 11 compliance.